Post COVID-19 vaccination Guillain-Barre syndrome: three cases

Seyyedehnarges Tabatabaei, Fatemeh Rezania, Sayed Mohammed Jawad Alwedaie, Ensieh Malekdar, Zahra Badi, Seyed Mohammad Tabatabaei, and Zahra Mirzaasgari

*Department of Neurology, Firoozi Hospital, School of Medicine, Iran university of medical sciences, Tehran, Iran; †Neurosciences Department, St Vincents Hospital, Melbourne, Australia; ‡Royal College of Surgeons in Ireland, Medical university of Bahrain, Manama, Bahrain; §Department of Neurology, Motamed Hospital, Garmser, Iran; ††Department of Neurology, Erfan Hospital, Tehran, Iran; ‡‡Department of Electrical and Computer Engineering, University of Tehran, Tehran, Iran; ‡§Shafa Neuroscience Research Center, Khatam Alainbia Hospital, Tehran, Iran

ABSTRACT

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship.

Introduction

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. GBS has also been repeatedly reported during or after severe COVID-19 infection. A number of vaccines have been shown to be associated with an increased risk of GBS. There have been increasing reports of GBS following vaccination. Temporally associated cases of GBS following COVID-19 vaccine have been described with messenger-RNA vaccine, adenovirus-vectored COVID-19 vaccine, and inactivated COVID-19 vaccines. Here, we describe three patients who developed GBS shortly after being vaccinated against COVID-19 with the AstraZeneca second dose and Sinopharm first dose in the absence of any other known precipitating factors.

Case 1

A 46-year-old man who was previously well presented with a one-week history of lower limbs weakness and 3 days of upper limbs weakness. His symptoms started three days after receiving the second dose of AstraZeneca vaccine. He described an ascending weakness together with pain in his lower limbs. He did not report back pain or bowel/bladder dysfunction. He denied fever, upper respiratory tract symptoms, or gastrointestinal illness leading up to his presentation. On examination, he was afebrile and hemodynamically stable. An evaluation of muscle power revealed Medical Research Council (MRC) grade +4/5 in upper limbs muscles, and MRC 4/5 in lower limbs. His deep tendon reflexes were absent in the ankles, 1+ in the knees and 2+ in biceps, triceps, and brachioradialis. All sensory modalities were intact in upper and lower limbs. His cranial nerve examinations were unremarkable.

Laboratory tests, including HIV viral serology, syphilis serology, and vasculitic screening showed negative results; however, his cerebrospinal fluid (CSF) examination revealed a high protein reading (184 mg/dL; reference range 15–45 mg/dL) with no cells. A nasopharyngeal (NP) swab and CSF for SARS-CoV-2 real-time polymerase-chain reaction (RT-PCR) test were negative. He underwent electromyography and nerve conduction studies (EMG-NCS) that showed features consistent with an acute motor axonal neuropathy (AMAN) subtype of GBS (Table 1). As a result, a diagnosis of GBS was considered. The patient was treated with 170-g intravenous immunoglobulin (IVIG) (2 g/kg) which resulted in partial improvement in his symptoms. (Table 2)

Case 2

A previously healthy 36-year-old man, presented to the Emergency Department with progressive generalized weakness, difficulty walking and clumsiness of his hands. He received his first dose of the Sinopharm vaccine five days prior to his presentation. He denied any history of prodromal infection prior to the onset of his symptoms.

He experienced a generalized weakness within the first 24 h after receiving his vaccination. However, his symptoms only progressed three days post vaccination with deterioration in his mobility requiring assistance for ambulation.

CONTACT Zahra Mirzaasgari mirzaasgari@gmail.com

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
The patient did not experience any sensory symptoms and gave no history of sphincteric dysfunction. He had a normal cranial nerve examination.

Motor examination demonstrated normal bulk and tone in bilateral upper and lower extremities. Strength in bilateral upper extremities was noted to be MRC 4/5. The examination of muscle strength in bilateral lower extremities showed MRC grade 3/5 in all muscle groups. Deep tendon reflexes were diminished in all four limbs. He had a normal sensory examination. There was no evidence of appendicular ataxia. MRI of the brain was normal. A NP swab for SARS-CoV-2 PCR test was negative. Routine lab tests were unrevealing. CSF examination showed a slight elevation of protein (54 mg/dL) with white cell count of 0. The patient underwent EMG-NCS that showed features consistent with an AMAN form of GBS (Table 3). This patient received an induction dose of IVIG (2 g/kg), which led to relative clinical improvement. (Table 2)

### Discussion

GBS is an inflammatory polyradiculoneuropathy that is usually precipitated by various infections and is one of the most common causes of acute flaccid paralysis, presenting with varying degrees of weakness, sensory abnormalities, and autonomic dysfunction. While the exact etiopathogenesis of GBS seems to be unclear, molecular mimicry and immune-mediated mechanisms like antiganglioside antibody production and complement activation are the most widely accepted theories. Approximately two-thirds of GBS cases happen to occur after an episode of infectious disease with 1–3 weeks interval. Various reports of GBS following COVID-19 infection have been published so far. Although a temporal relationship between GBS and some vaccines has been reported, the establishment of a causal link is proved to be controversial. Nevertheless, a small increase in the incidence of GBS after influenza vaccination is relatively well established. It is prudent to closely monitor the potential adverse events of COVID-19 vaccines such as COVID-19 vaccination-associated GBS. Recently, the co-occurrence of GBS with various COVID-19 vaccines has been reported. Likewise, we described a temporal link between receiving Sinopharm and AstraZeneca COVID-19 vaccines and GBS onset within 34–14 days after injection. To date, the most common reported side effects of COVID-19 vaccines are injection site reactions, flu-like complaint, headache, and asthenia that mostly are mild and self-limiting conditions and do not require any intervention.

We report the first cases of GBS post COVID-19 vaccination in Iran that initially presented with the typical GBS symptoms of ascending weakness. This is in contrast to the previous three published case reports, which have described 12 patients in

### Table 1. Nerve conduction study parameters in patient 1.

| Nerve stimulated | Stimulation site | Recording site | Amplitude* | Latency (ms) | Conduction velocity (m/s) | F wave latency (ms) |
|------------------|------------------|----------------|------------|--------------|--------------------------|-------------------|
|                  |                  |                | Rt         | Lt           | Ref                      | Rt         | Lt           | Ref | Rt         | Lt           | Ref | 
| Median (M)       | Wrist            | APB            | 1.1        | 1.2          | ≥4                       | 4.6        | 4.1          | ≤4.4| NM         | NM           | ≤31 |
|                  | AF               | APB            | 1.1        | 1.3          | 9.25                     | 8.9        | 55.9         | 54.2| ≥49        | NM           | ≤32 |
| Ulnar (M)        | Wrist            | ADM            | 1.7        | 1.0          | ≥6                       | 3          | 3.65         | ≤3.3| 58         | 59           | ≥49 |
|                  | BE               | ADM            | 1.5        | 0.9          | 1.2                      | 0.8        | 56           | 60  | ≥49        | NM           | ≤32 |
| Tibial (M)       | Ankle            | AHB            | 1.0        | 0.3          | ≥4                       | 4.95       | 8.0          | ≤5.8| 40         | 45           | ≥41 |
|                  | PF               | AHB            | 0.8        | 0.3          | 1.2                      | 1.0        | 5.4          | ≤5.6| 48.1       | 44           | ≥44 |
| Peroneal (M)     | Ankle            | EDB            | 0.9        | 0.3          | ≥2                       | 6.5        | 7.7          | ≤6.5| 48.1       | 44           | ≥44 |
|                  | BF               | EDB            | 0.8        | 0.3          |                           |            |              |     | 48.4       | 44           | ≥44 |
|                  | LPF              | EDB            | 0.7        | 0.2          |                           |            |              |     | 47.1       | 44           | ≥44 |
| Median (S)       | Wrist            | Digit 2        | 28         | 26           | ≥20                      | 3.75       | 3.85         | ≤3.5| 40         | 45           | ≥50 |
| Ulnar (S)        | Wrist            | Digit 5        | 19.8       | 18.7         | ≥17                      | 3.4        | 3.4          | ≤3.4| 45         | 45           | ≥50 |
| Sural (S)        | Calf             | Post. ankle    | 16.6       | 14.5         | ≥6                       | 4.6        | 4.4          | ≤4.4| 53         | 52           | ≥40 |

There was significant drop in compound muscle action potential (CMAP) amplitude in 4 limbs with preserved conduction velocity and F-wave latency (were tested). Sensory responses were normal in 4 limbs. These findings were in keeping with acute motor axonal neuropathy (AMAN) subtype of GBS. M = motor responses; S = antidromic sensory responses; ms = milli second; m/s = meter per second; Rt = right; Lt = left; Ref = Reference range; NM = not measured; AF = anterior fossa; BE = below elbow; AE = above elbow; BF = below fibula; LPF = lateral posterior fossa; APB = abductor pollicis brevis; ADM = abductor digiti minimi; AHB = abductor hallucis brevis; EDB = extensor digitorum brevis.

*Motor studies’ amplitudes measured in millivolts (mV) and sensory studies’ amplitudes measured in microvolts (μV).
Table 2. Characteristics of three patients with GBS after the COVID-19 vaccination.

| Patient No. | Characteristics | Symptoms Onset of Neurologic | COVID-19 Vaccine and Timeline of Symptoms | Neurologic Signs and Symptoms | CSF analysis | EMG-NCS subtype | Treatment | Outcome |
|-------------|-----------------|-------------------------------|-------------------------------------------|-----------------------------|--------------|-----------------|-----------|---------|
| 1           | 46-year-old male | 7 days prior to admission     | AstraZeneca, 3 days after the second dose | Progressive ascending quadriparesthesia, Decreased or absent DTR in weak limbs | Elevated protein level (184 mg/dl) no cells | AMAN           | 170 g IVIG physiotherapy | Relative improvement |
| 2           | 36-year-old male | 5 days prior to presentation  | Sinopharm, 5 days after the first dose    | Progressive generalized weakness, diminished DTR in all limbs | Elevated protein level (54 mg/dL) WBC <10 (normal) | AMAN           | 160 g IVIG physiotherapy | Relative improvement |
| 3           | 32-year-old male | 4 days prior to presentation  | Sinopharm, 14 days after the first dose   | Progressive ascending quadriparesthesia, Decreased or absent DTR in weak limbs diarrhea | Protein level (30 mg/dL) no cells | AMAN           | 185 g IVIG physiotherapy | Relative improvement |

EMG-NCS: electromyography and nerve conduction studies; CSF: cerebrospinal fluid; IVIG: intravenous immunoglobulin; AMAN: acute motor axonal neuropathy; DTR: Deep tendon reflex.
Table 3. Nerve conduction study parameters in patient 2.

| Nerve stimulated | Stimulation site | Recording site | Amplitude* | Latency (ms) | Conduction velocity (m/s) | F wave latency (ms) |
|------------------|-----------------|----------------|------------|--------------|--------------------------|------------------|
|                  |                 |                | Rt         | Lt           | NI                        |                  |
| Median (m)       | Wrist           | APB            | 3.1        | 2.9          | ≥4                       | 4.10             | 3.80            | ≤4.4            | ≤31             |
|                  |                 |                |            |              |                          |                  |
| Ulnar (M)        | Wrist           | ADM            | 3.5        | 2.6          | ≥6                       | 2.75             | 2.63            | ≤3.3            | 54.2            | 51.3            | ≥49             |
|                  |                 |                |            |              |                          |                  |
| Tibial (M)       | Ankle           | AHB            | 1.1        | 0.8          | ≥4                       | 5.20             | 5.35            | ≤5.8            | 43.5            | 40.7            | ≥49             |
|                  |                 |                |            |              |                          |                  |
| Peroneal (M)     | Ankle           | EDB            | 1.3        | 1.5          | ≥2                       | 7.20             | 8.10            | ≤6.5            | 51.7            | 54.2            | 62               | 67               | ≤56             |
|                  |                 |                |            |              |                          |                  |
| Median (S)       | Wrist           | Digit 2        | 28.0       | 32.0         | ≥20                      | 3.65             | 3.40            | ≤3.5            | 38.5            | 42.5            | ≥50             |
|                  |                 |                |            |              |                          |                  |
| Ulnar (S)        | Wrist           | Digit 5        | 35.4       | 32.3         | ≥17                      | 2.80             | 2.90            | ≤3.1            | 45.9            | 44.3            | ≥50             |
|                  |                 |                |            |              |                          |                  |
| Sural (S)        | Calf            | Post. ankle    | 13.4       | 14.5         | ≥6                       | 4.15             | 4.35            | ≤4.4            | 31.7            | 34.8            | ≥40             |

There was significant drop in compound muscle action potential (CMAP) amplitude in 4 limbs with preserved conduction velocity and F-wave latency (were tested). Sensory responses were normal in 4 limbs. These findings were in keeping with acute motor axonal neuropathy (AMAN) subtype of GBS. M= motor responses, S= antidromic sensory responses; ms = milli second, m/s = meter per second; Rt = right; Lt = left; Ref = Reference range; NM = not measured; AF = anterior fossa; BE = below elbow; AE = above elbow; BF = below fibula; LPF = lateral posterior fossa; APB = abductor pollicis brevis; ADM = abductor digiti minimi; AHB = abductor hallucis brevis; EDB = extensor digitorum brevis.

*Motor studies’ amplitudes measured in millivolts (mV) and sensory studies’ amplitudes measured in microvolts (μV).

total with post AsteraZeneca vaccine GBS within all of them having uncommon presentation of bilateral facial weakness as presenting symptom.6,7,19 Various subtypes of GBS differ clinically and electrophysiologically. However, GBS typically presents with a symmetric weakness of both upper and lower limbs with depressed or complete lack of reflexes (areflexia).11 To the best of our knowledge, there have been only three cases of GBS after the COVID-19 Sinopharm vaccine reported so far in the literature.8 Here, we described two further cases of GBS associated with COVID-19 Sinopharm vaccine. Post vaccine GBS has been mostly shown to be an acute inflammatory demyelinating polyradiculoneuropathy (AIDP) subtype electrophysiologically,20-22 in contrast to our cases of AMAN subtype of GBS. Despite reports on higher morbidity and mortality rates in AMAN patients, especially in those with lower CMAPs amplitudes,22,23 our patients showed a considerable short-term improvement after receiving IVIG therapy.

Given the current situation of the COVID-19 pandemic, vaccination against this virus has become one of the most imperative strategic plans in many countries. Several mechanisms may be involved in the association of autoimmune diseases after vaccination such as the cross reaction of contaminating proteins or other vaccine components that share similarities with myelin or axon epitopes with peripheral nerves.24 An extensive epidemiological study has not been performed yet to investigate the relationship between GBS after COVID-19 vaccination. However, since GBS is a debilitating disease, a diligent reporting of these rare adverse events on the safety of the COVID-19 vaccine not only allows physicians to recognize and treat this rare condition in a timely fashion but also enables scientists with an opportunity to further investigate a potential link between GBS and COVID-19 vaccination.

Table 4. Nerve conduction study parameters in patient 3.

| Nerve stimulated | Stimulation site | Recording site | Amplitude* | Latency (ms) | Conduction velocity (m/s) | F wave latency (ms) |
|------------------|-----------------|----------------|------------|--------------|--------------------------|------------------|
|                  |                 |                | Rt         | Lt           | NI                        |                  |
| Median (M)       | Wrist           | APB            | 3.5        | 3.6          | ≥4                       | 4.15             | 3.75            | ≤4.4            | ≤31             |
|                  |                 |                |            |              |                          |                  |
| Ulnar (M)        | Wrist           | ADM            | 3.9        | 2.3          | ≥6                       | 2.65             | 2.75            | ≤3.3            | 57.1            | 54.2            | ≥49             |
|                  |                 |                |            |              |                          |                  |
| Tibial (M)       | Ankle           | AHB            | 1.3        | 0.9          | ≥4                       | 5.45             | 5.7             | ≤5.8            | 47.3            | 41.7            | ≥49             |
|                  |                 |                |            |              |                          |                  |
| Peroneal (M)     | Ankle           | EDB            | 1.5        | 1.8          | ≥2                       | 7.40             | 8.65            | ≤6.5            | 54.4            | 59.3            | 65               | 68               | ≤56             |
|                  |                 |                |            |              |                          |                  |
| Median (S)       | Wrist           | Digit 2        | 35.0       | 42.0         | ≥20                      | 3.85             | 3.50            | ≤3.5            | 37.5            | 41.5            | ≥49             |
|                  |                 |                |            |              |                          |                  |
| Ulnar (S)        | Wrist           | Digit 5        | 37.7       | 40.1         | ≥17                      | 2.90             | 3.00            | ≤3.1            | 46.8            | 47.9            | 50               |
|                  |                 |                |            |              |                          |                  |
| Sural (S)        | Calf            | Post. calf     | 12.1       | 15.5         | ≥6                       | 3.85             | 4.40            | ≤4.4            | 32.4            | 36.7            | ≥40             |

There was significant drop in compound muscle action potential (CMAP) amplitude in 4 limbs with preserved conduction velocity and F-wave latency (were tested). Sensory responses were normal in 4 limbs. These findings were in keeping with acute motor axonal neuropathy (AMAN) subtype of GBS. M= motor responses, S= antidiomorphic sensory responses; ms = milli second, m/s = meter per second; Rt = right; Lt = left; Ref = Reference range; NM = not measured; AF = anterior fossa; BE = below elbow; AE = above elbow; BF = below fibula; LPF = lateral posterior fossa; APB = abductor pollicis brevis; ADM = abductor digiti minimi; AHB = abductor hallucis brevis; EDB = extensor digitorum brevis.

*Motor studies’ amplitudes measured in millivolts (mV) and sensory studies’ amplitudes measured in microvolts (μV).
Abbreviations

GBS  Guillain-Barré syndrome
MRC  Medical Research Council
CSF  cerebrospinal fluid
NP  nasopharyngeal
RT-PCR  real time polymerase chain reaction
EMG-NCS  electromyography and nerve conduction studies
AMAN  acute motor axonal neuropathy
IVIG  intravenous immunoglobulin
AIDP  acute inflammatory demyelinating polyradiculoneuropathy

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

ORCID

Sayed Mohammed Jawad Alwedaei http://orcid.org/0000-0003-0101-2137
Zahra Mirzaasgari http://orcid.org/0000-0002-4046-8471

References

1. Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, van Doorn PA, Durado ME, Hughes RA, Islam B, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83. doi:10.1038/s41582-019-0250-9.
2. Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001;14(5):605–13. doi:10.1097/00019052-200110000-00009.
3. Abolmaali M, Heidari M, Zeinali M, Moghadam P, Ghamarsi MR, Makiani MJ, Mirzaasgari Z. Guillain-Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series. J Clin Neurosci. 2021;83:119–22. doi:10.1016/j.jocn.2020.11.013.
4. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2). doi:10.7759/cureus.13426.
5. Loza AMM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021;96(22):1052–54. doi:10.1212/WNL.000000000011881.
6. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Namboothiri S, Syed AA, Mangat HS. Guillain-Barré syndrome following ChAdOx1-S-nCoV-19 vaccine. Ann Neurol. 2021;90(2):312–14. doi:10.1002/ana.26143.
7. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasecu R, Evans JR. Guillain–barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90(2):315–18. doi:10.1002/ana.26144.
8. Karimi N, Boostani R, Fatehi F, Panahi A, Okhovat AA, Ziaadini B, Basiri K, Abdi S, Sinaei F, Rezaei M, et al. Guillain-Barré syndrome and COVID-19 vaccine: a report of nine patients. Basic Clin Neurosci. 12(5):703–10. doi:10.3259/bcn.2021.35651.
9. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27. doi:10.1016/S0140-6736(16)00339-1.
10. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and guillian-barre syndrome. Drug Safety. 2009;32(4):309–23. doi:10.2165/00003495-200932040-00005.
11. Van Den Berg B, Walgaard C, Drenthen J, Fukke C, Jacobs BC, Van Doorn PA. Guillain–barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82. doi:10.1038/nrn4101.121.
12. Jacobs B, Rothbarth P, Van der Meché F, Herbrink P, Schmitz P, De Klerk M, van Doorn PA. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110–15. doi:10.1212/WNL.51.4.1110.
13. Bardage C, Persson I, Örtqvist Å, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ. 2011;343:oct12 2:d5956. doi:10.1136/bmj.d5956.
14. Cao-Lormeau V-M, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–39. doi:10.1016/S0140-6736(16)00562-6.
15. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenleyside RA, Ziegler DW, Retaliulia HF, Eddins DL, Bryan JA. Guillain-Barré syndrome following vaccination in the national influenza immunization program, united states, 1976–1977. Am J Epidemiol. 1979;110(2):105–23. doi:10.1093/oxfordjournals.aje.a112795.
16. Patel SU, Khurram R, Lakhan A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021;2021(4):e242956. doi:10.1136/bcr-2021-242956.
17. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shchelbylyakov DY, Dzhuriilovaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, et al. Safety and immunogenicity of an Ad26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97. doi:10.1016/S0140-6736(20)31866-3.
18. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324(10):951–60. doi:10.1001/jama.2020.15543.
19. McKean N, Chicop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep. 2021;2021(4):e2021244125.
20. Oo WM, Giri P, De Souza A. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Thailand: a causal link? J Neuroimmunol. 2021;360:577719. doi:10.1016/j.jneuroim.2021.577719.
21. James J, Jose J, Galoor VA, Smita B, Balaram N. Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series. Neurol Clin Neurosci. 2021;9(5):402–05. doi:10.1111/ncn.12357.
22. Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, Feasby TE, Quaskey SA. Motor conduction studies in guillain-barré syndrome: description and prognostic value. Ann Neurol. 1988;23(4):354–59. doi:10.1002/ana.410230407.
23. Akbarayam S, Doğan M, Akgün C, Peker E, Sayın R, Aktar F, Bekşas MS, Çalışken H. Clinical features and prognosis with Guillain-Barré syndrome. Ann Indian Acad Neurol. 2011;14(2):98. doi:10.4103/0972-2327.82793.
24. Vadala M, Poddighie D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? Epma J. 2017;8(3):295–311. doi:10.1007/s13167-017-0101-y.